Coronavirus company news summary - INOVIO to start Phase III trial of DNA vaccine candidate - Revive and Supriya partner to pursue Indian EUA for bucillamine against Covid-19
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – INOVIO to start Phase III trial of DNA vaccine candidate – Revive and Supriya partner to pursue Indian EUA for bucillamine against Covid-19

09 Jun 2021 (Last Updated June 9th, 2021 11:46)

INOVIO has expanded its partnership with Advaccine Biopharmaceuticals to conduct the global Phase III segment of an ongoing Phase II/III trial called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). As per the agreement, the companies will be examining the safety and efficacy of administering INO-4800, INOVIO’s DNA vaccine candidate against SARS-CoV-2, in two doses, a month apart, in a two-to-one randomisation in participants aged 18 years and older across several countries, chiefly in Asia and Latin America.

Revive Therapeutics has signed a memorandum of understanding (MoU) with Indian-based Supriya Lifescience to pursue emergency use authorisation (EUA) of bucillamine as a treatment for Covid-19 in India. The company seeks to clinically register and commercialise the therapeutic by leveraging Supriya’s API manufacturing and commercial network, and by presenting results from its ongoing US Food and Drug Administration (FDA) Phase III clinical trial of bucillamine in treating mild-to-moderate Covid-19.

Researchers from the Baylor College of Medicine have launched a clinical study to assess the safety and efficacy of a booster dose of Moderna’s mRNA-1273 Covid-19 vaccine. The trial is for individuals who have already been vaccinated with one of the vaccines approved by the FDA for emergency use. The second phase of the trial will include participants who have never received a Covid-19 vaccine jab or have been previously infected with the SARS-CoV-2 virus to evaluate the immune response to a booster dose after receiving the Moderna vaccine.